AzTrials
AzTrials

PainNCT01045993

A Study To Evaluate Methods To Evaluate Back Pain

A study testing Heat Device and marketed analgesic in people with Pain, run by Wyeth is now a wholly owned subsidiary of Pfizer at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study is designed to assess methods used in clinical research. Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Pain
What is being tested?
Heat Device and marketed analgesic
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
61 participants
Where
1 siteUnited States
Study dates
Feb 2010to Jul 2010
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Lower back pain
  • Male or female in generally good health, from 18 to 55 years of age (inclusive)

Who cannot join

  • Pregnant or lactating
  • Subject has evidence or history of radiculopathy, i.e. sciatica extending below the knee (numbness, tingling, or shooting pain), or other neurologic deficits (abnormal straight leg raise test, patellar reflexes, and/or bowel and bladder function);
  • Subject has a history of previous back surgery;
  • Subject has back pain resulting from traumatic injury involving physical evidence of bruising, swelling, or inflammation to the abdomen or low back area which occurred less than 48 hours prior to enrollment
  • Has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study
  • Is a member or relative of the study site staff, CRO or Sponsor organization directly involved with the study or had a household member or relative participate concurrently or previously in this study
  • Has previously been enrolled in this study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Pfizer Investigational Site

    Loma Linda, California, 92350

Other trials in United States

About this study

Official title: A Pilot Study To Evaluate Various Methodologies For Assessing The Treatment Of Low Back Pain

The study is designed to assess methods used in clinical research.

Conditions
Pain
Being tested
Heat Device, Sham Device, marketed analgesic, Placebo
Keywords
Pilot Study to Assess Methodologies
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Heat DeviceDevice

    Also called Heatwrap

    8-Hour Heatwrap

  • Sham DeviceDevice

    Inactive wrap worn for 8 hours

  • marketed analgesicDrug

    2 x 200 mg ibuprofen tablets

  • PlaceboDrug

    2 x placebo tablets

Study groups in NCT01045993
Study groupRoleWhat they receive
1Active comparatorHeat device
Receives: Device: Heat Device
2Sham comparatorPlacebo arm
Receives: Device: Sham Device
3Active comparatorMarketed analgesic
Receives: Drug: marketed analgesic
4Placebo comparator(Oral) Placebo comparator
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to First Perceptible Relief (Confirmed by Meaningful Relief)

    "First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first stopwatch was depressed. Confidence interval (CI) calculated using the method of Simon \& Lee.

    Measured: Baseline (time of wrap application or oral treatment administration) up to 4 hours

Secondary outcomes (16)
  1. Time to Meaningful Relief

    Time to "meaningful relief" defined as elapsed time from start of treatment until participant depressed the second stopwatch indicating "meaningful relief" (meaningful to participant). Participant consider censored if participant did not depress the stopwatch by end of 4-hour in-patient evaluation, or became a treatment failure (rescue or discontinuation) during the time prior to depressing the second stopwatch. Censoring was at time of dropout if participant withdrew for non-efficacy related reasons during the 4-hour in-patient portion of the study. CI calculated using method of Simon \& Lee.

    Measured: Baseline (time of wrap application or oral treatment administration) up to 4 hours

  2. Time Weighted Sum of Pain Relief From 0 Through 8 Hours (TOTPAR 0-8)

    TOTPAR 0-8 sum of pain relief from 0 through 8 hours, weighted by the time duration between the current timepoint and the previous timepoint. Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief. Total possible score 0 to 40; higher score indicated better relief.

    Measured: Baseline (time of wrap application or oral treatment administration) up to 8 hours

  3. Time Weighted Sum of Change From Baseline in the Back Stiffness Score Over 8 Hours

    Time weighted sum of change calculated as sum of change from baseline in back stiffness scores from 0 through 8 hours, weighted by time duration between current timepoint and previous timepoint. Based on hourly (from baseline) back stiffness assessment rating from 0 (no muscle stiffness) to 100 (most possible muscle stiffness). Sum of change derived by subtracting score at post-dosing time point from baseline score. Total possible score -800 to 800; higher positive value was indicative of greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) up to 8 hours

  4. Time to Treatment Failure

    Time to treatment failure defined as time from dosing to the time of rescue medication within the scheduled duration of the study (8 hours); or for participants who withdrew from the study due to lack of efficacy without taking rescue medication, the time of the last assessment was considered the time to treatment failure; or if participant did not take rescue medication, or did not discontinue due to lack of efficacy, the time to treatment failure was considered censored at 8 hours (the scheduled duration of the study).

    Measured: Baseline (time of wrap application or oral treatment administration) up to 8 hours

  5. Individual Time-Point Pain Relief Scores

    Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief.

    Measured: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes

  6. Change From Baseline in Individual Time-point Back Stiffness Scores

    Low back muscle stiffness rated hourly (from baseline) by the participant by placing a line on a visual analog scale (VAS) from 0 millimeters (mm) to 100 mm in length with 0=no muscle stiffness up to 100 (most possible stiffness).

    Measured: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes

  7. Change From Baseline (Bsl) in Combined Flexibility Score: Extension

    Flexibility assessed using Paris Plinth table with maximum extension (as if performing a sit-up) of 20 degrees movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees minus 5, and x degrees plus 5. Flexibility score derived using standardized value and VAS score (participant rating of pain by marking level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for extension flexibility were average of the extension flexibility data on the combined score (range -66 to 552); higher value indicated greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  8. Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side

    Flexibility assessed using Paris Plinth table with maximum side-to-side movement of plus or minus (+/-) 10 degrees for left, and right (L, R), movement. Angle at Bsl and 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain to 100=worst pain). Final derived data for overall flexibility was the average of side-to-side (L, R) flexibility data on the combined score (range -81 to 264); higher value=greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  9. Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation

    Flexibility assessed using Paris Plinth table with maximum rotation at waist of plus or minus (+/-) 30 degrees for left, and right (L, R), movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for overall flexibility were the average of rotation (L, R) flexibility data on combined score (range -80 to 155); higher value=greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  10. Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Extension

    Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement of 20 degrees for extension (as if performing a sit-up) to the degree of movement at which participant perceives discomfort or pain. Higher score indicated greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  11. Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Side-to-Side

    Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement +/- 10 degrees for left, and right, side-to-side movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right side-to-side scores. Higher score indicated greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  12. Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Rotation

    Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum rotation at waist of +/- 30 degrees for left, and right, movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right rotation scores. Higher score indicated greater improvement.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  13. Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension

    Flexibility assessed using Paris Plinth table with maximum extension of 20 degrees movement (as if performing a sit-up). When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Higher score indicated greater discomfort/pain.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  14. Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side

    Flexibility assessed using Paris Plinth table with maximum side-to-side movement of +/- 10 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  15. Change From Baseline in Pain Measurement for Flexibility Measure: Rotation

    Flexibility assessed using Paris Plinth table with maximum rotation at waist of +/- 30 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.

    Measured: Baseline (time of wrap application or oral treatment administration) and 4 hours

  16. Number of Participants Per Categorical Score for Global Assessment of Study Treatment

    At hour 8, or at the time of rescue, if it occurred, participants performed a global assessment in their diary in response to the question: How would you rate the study treatment as a pain reliever? Very Poor=0, Poor=1, Fair=2, Good=3, Very Good=4, Excellent=5.

    Measured: Baseline (time of wrap application or oral treatment administration) up to 8 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2010 (estimated)
  2. Study startFeb 2010
  3. Primary completionJul 2010
  4. Study completionJul 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01045993
Sponsor's protocol ID
TC-09-20
Status last verified
Feb 2013
First submitted
8 Jan 2010
Last updated
1 Apr 2013
Data monitoring committee
No

Publications

  • Stark J, Petrofsky J, Berk L, Bains G, Chen S, Doyle G. Continuous low-level heatwrap therapy relieves low back pain and reduces muscle stiffness. Phys Sportsmed. 2014 Nov;42(4):39-48. doi: 10.3810/psm.2014.11.2090.

    PubMed 25419887

Questions about this trial

What is this clinical trial studying?

A study testing Heat Device and marketed analgesic in people with Pain, run by Wyeth is now a wholly owned subsidiary of Pfizer at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Apr 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to First Perceptible Relief (Confirmed by Meaningful Relief) (time frame: Baseline (time of wrap application or oral treatment administration) up to 4 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01045993, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2013.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
A Study To Evaluate Methods To Evaluate Back Pain | AzTrials